Table 4.
Sensitivity and specificity for the sCD26 at the cut-off value of 460 ng/mL
| Cohort | nsCD26+/nt | Sensitivity (95% CI) |
|---|---|---|
| CRC | 27/33 | 81.8% (64.5-93.0) |
| Advanced adenomas | 20/48 | 41.7% (27.6-56.8) |
| CRC and advanced adenomas | 47/81 | 58.0% (46.5-68.9) |
| Non-advanced adenomas and advanced adenomas | 30/88 | 34.1% (24.3-45.0) |
| Cohort | nsCD26-/nt | Specificity (95% CI) |
| No colorectal findings-no symptoms | 27/30 | 90.0% (73.4-97.8) |
| No colorectal findings | 54/68 | 79.4% (67.9-88.3) |
| No colorectal findings, non-IBD, IBD, hyperplastic polyps, non-advanced and advanced adenomas | 191/264 | 72.3% (65.0-77.2) |
| No colorectal findings, non-IBD, IBD, hyperplastic polyps and non-advanced adenomas | 163/216 | 75.5% (68.5-81.0) |
nsCD26+: number of individuals with sCD26 levels ≤ 460 ng/mL; nsCD26-: number of individuals with sCD26 levels > 460 ng/mL; nt: total number of individuals per group.